Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX® mesalamine
Authors:
Open Access
- 1 July 2012
- journal article
- Published by Taylor & Francis in Clinical Pharmacology: Advances and Applications
- Vol. 4, 41-50
Abstract
Peer reviewed article authored by (Nanda K, Moss AC). Read article or submit your manuscript for publishing.Keywords
This publication has 87 references indexed in Scilit:
- Health-Related Quality of Life in Patients with Ulcerative Colitis After a 10-year Disease Course: Results from the IBSEN StudyInflammatory Bowel Diseases, 2012
- Decreasing Risk of Colorectal Cancer in Patients With Inflammatory Bowel Disease Over 30 YearsGastroenterology, 2012
- Once-Daily Dosing vs. Conventional Dosing Schedule of Mesalamine and Relapse of Quiescent Ulcerative Colitis: Systematic Review and Meta-AnalysisAmerican Journal of Gastroenterology, 2011
- Ulcerative Colitis Practice Guidelines in Adults: American College of Gastroenterology, Practice Parameters CommitteeAmerican Journal of Gastroenterology, 2010
- A cost-effectiveness analysis of MMX mesalazine compared with mesalazine in the treatment of mild-to-moderate ulcerative colitis from a UK perspectiveJournal of Medical Economics, 2009
- The risk of colorectal cancer in ulcerative colitis: a meta-analysisGut, 2001
- A Meta-Analysis and Overview of The Literature on Treatment Options for Left-Sided Ulcerative Colitis and Ulcerative ProctitisAmerican Journal of Gastroenterology, 2000
- Mesalazine-associated interstitial nephritisNephrology Dialysis Transplantation, 1996
- Clinical Pharmacokinetics of Sulphasalazine, Its Metabolites and Other Prodrugs of 5-Aminosalicylic AcidClinical Pharmacokinetics, 1985
- Sulfasalazine inhibits the synthesis of chemotactic lipids by neutrophils.Journal of Clinical Investigation, 1982